Omalizumab Improves Angioedema-Related Quality of Life Impariment in Patients with Chronic Idiopathic/Chronic Spontaneous Urticaria: Results from the X-Act Study

SKIN The Journal of Cutaneous Medicine(2018)

Cited 0|Views0
No score
Abstract
Abstract not available. Disclosures: Study supported by Novartis. Copyright 2018 SKIN
More
Translated text
Key words
chronic spontaneous urticaria,omalizumab,chronic idiopathic/chronic,angioedema-related,x-act
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined